Developing Oncolytic Viruses for the Treatment of Cervical Cancer

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2023 Jul 29

PMID 37508503

Authors

Eleni Kalafati

Ekati Drakopoulou

Nicholas P Anagnou

Kalliopi I Pappa

Affiliations

Soon will be listed here.

Abstract

Cervical cancer represents one of the most important malignancies among women worldwide. Current therapeutic approaches for cervical cancer are reported not only to be inadequate for metastatic cervical cancer, but are also considered as cytotoxic for several patients leading to serious side effects, which can have negative implications on the quality of life of women. Therefore, there is an urgent need for the development of innovative and effective treatment options. Oncolytic viruses can eventually become effective biological agents, since they preferentially infect and kill cancer cells, while leaving the normal tissue unaffected. Moreover, they are also able to leverage the host immune system response to limit tumor growth. This review aims to systematically describe and discuss the different types of oncolytic viruses generated for targeting cervical cancer cells, as well as the outcome of the combination of virotherapy with conventional therapies. Although many preclinical studies have evaluated the therapeutic efficacy of oncolytic viruses in cervical cancer, the number of clinical trials so far is limited, while their oncolytic properties are currently being tested in clinical trials for the treatment of other malignancies.

Citing Articles

Oncolytic activity of a coxsackievirus B3 strain in patient-derived cervical squamous cell carcinoma organoids and synergistic effect with paclitaxel.

Lin Y, Liu N, Yang C, Tan H, Fang C, Yu K Virol J. 2024; 21(1):245.

PMID: 39369233 PMC: 11452971. DOI: 10.1186/s12985-024-02502-y.

Clinical Application of Adenovirus (AdV): A Comprehensive Review.

Salauddin M, Saha S, Hossain M, Okuda K, Shimada M Viruses. 2024; 16(7).

PMID: 39066256 PMC: 11281619. DOI: 10.3390/v16071094.

A viral attack on brain tumors: the potential of oncolytic virus therapy.

Mokhtarpour K, Akbarzadehmoallemkolaei M, Rezaei N J Neurovirol. 2024; 30(3):229-250.

PMID: 38806994 DOI: 10.1007/s13365-024-01209-8.

The Evolving Landscape of Cervical Cancer: Breakthroughs in Screening and Therapy Through Integrating Biotechnology and Artificial Intelligence.

Aswathy R, Sumathi S Mol Biotechnol. 2024; 67(3):925-941.

PMID: 38573545 DOI: 10.1007/s12033-024-01124-7.

References

Harrington K, Karapanagiotou E, Roulstone V, Twigger K, White C, Vidal L . Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res. 2010; 16(11):3067-77. PMC: 3907942. DOI: 10.1158/1078-0432.CCR-10-0054. View

Harrington K, Hingorani M, Tanay M, Hickey J, Bhide S, Clarke P . Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res. 2010; 16(15):4005-15. DOI: 10.1158/1078-0432.CCR-10-0196. View

Hu Z, Ma D . The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med. 2018; 7(10):5217-5236. PMC: 6198240. DOI: 10.1002/cam4.1501. View

Keshavarz M, Mozaffari Nejad A, Esghaei M, Bokharaei-Salim F, Dianat-Moghadam H, Keyvani H . Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis. Saudi J Biol Sci. 2020; 27(1):47-52. PMC: 6933251. DOI: 10.1016/j.sjbs.2019.04.015. View

Olusola P, Banerjee H, Philley J, Dasgupta S . Human Papilloma Virus-Associated Cervical Cancer and Health Disparities. Cells. 2019; 8(6). PMC: 6628030. DOI: 10.3390/cells8060622. View

Blackford A, Grand R . Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation. J Virol. 2009; 83(9):4000-12. PMC: 2668481. DOI: 10.1128/JVI.02417-08. View

Singh N, Senapati S, Bose K . Insights into the mechanism of human papillomavirus E2-induced procaspase-8 activation and cell death. Sci Rep. 2016; 6:21408. PMC: 4764946. DOI: 10.1038/srep21408. View

Todo T, Martuza R, Rabkin S, Johnson P . Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001; 98(11):6396-401. PMC: 33479. DOI: 10.1073/pnas.101136398. View

Huang Q, Li F, Liu X, Li W, Shi W, Liu F . Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med. 2011; 17(7):860-6. PMC: 3132290. DOI: 10.1038/nm.2385. View

10.

Burucua M, Perez S, Odeon A, Cobo E, Quintana S, Marin M . Cathelicidin bovine myeloid antimicrobial peptide (BMAP) 28 is involved in the inflammatory response against alpha-herpesviruses in the bovine nervous system. Mol Immunol. 2020; 122:148-155. DOI: 10.1016/j.molimm.2020.04.017. View

11.

Saxena L, Kumar G, Saxena S, Chaturvedi U, Sahoo A, Singh L . Apoptosis induced by NS1 gene of Canine Parvovirus-2 is caspase dependent and p53 independent. Virus Res. 2013; 173(2):426-30. DOI: 10.1016/j.virusres.2013.01.020. View

12.

Karcher J, Dyckhoff G, Beckhove P, Reisser C, Brysch M, Ziouta Y . Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res. 2004; 64(21):8057-61. DOI: 10.1158/0008-5472.CAN-04-1545. View

13.

Bauerschmitz G, Kanerva A, Wang M, Herrmann I, Shaw D, Strong T . Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer. Int J Cancer. 2004; 111(2):303-9. DOI: 10.1002/ijc.20217. View

14.

Kulkarni A, Ferreira T, Bretscher C, Grewenig A, El-Andaloussi N, Bonifati S . Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry. Nat Commun. 2021; 12(1):3834. PMC: 8219832. DOI: 10.1038/s41467-021-24034-7. View

15.

Bauerschmitz G, Barker S, Hemminki A . Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). Int J Oncol. 2002; 21(6):1161-74. View

16.

Spear M, Sun F, Eling D, Gilpin E, Kipps T, Chiocca E . Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther. 2000; 7(7):1051-9. DOI: 10.1038/sj.cgt.7700208. View

17.

Kyula J, Roulstone V, Karapanagiotou E, Melcher A, Harrington K . Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer. Expert Opin Biol Ther. 2012; 12(12):1669-78. DOI: 10.1517/14712598.2012.745507. View

18.

Chang J, Zhao X, Wu X, Guo Y, Guo H, Cao J . A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol Ther. 2009; 8(8):676-82. DOI: 10.4161/cbt.8.8.7913. View

19.

Kim J, Kim J, Choi K, Kim P, Yun C . E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Hum Gene Ther. 2007; 18(9):773-86. DOI: 10.1089/hum.2006.167. View

20.

Marchini A, Bonifati S, Scott E, Angelova A, Rommelaere J . Oncolytic parvoviruses: from basic virology to clinical applications. Virol J. 2015; 12:6. PMC: 4323056. DOI: 10.1186/s12985-014-0223-y. View